Products Satralizumab was approved in many countries in 2020 as a solution for injection (Enspryng). Structure and properties Satralizumab is a humanized IgG2 monoclonal antibody produced by biotechnological methods. Effects Satralizumab (ATC L04AC19) has anti-inflammatory and immunosuppressive properties. The effects are due to binding to the soluble and membrane-bound human IL-6 receptor (IL-6R), preventing signal … Satralizumab
Products In late September 2016, the first so-called “artificial pancreas” was approved in the United States, Medtronic’s MiniMed 670G system. The system will be available by physician prescription in spring 2017. How it works The device measures glucose levels every five minutes with a sensor under the skin (subcutaneous) in tissue fluid and automatically delivers … Artificial Pancreas
Products Anthroposophic mistletoe extract Iscador is commercially available in many countries as a solution for injection. It was developed from 1916 by the founder of anthroposophy, Rudolf Steiner (1861-1925) and the physician Ita Wegmann. In addition to Iscador, another product was later launched (Helixor, Swissphar). This article refers to Iscador. Structure and properties The aqueous … Anthroposophic Mistletoe Extract
Products Octreotide is commercially available as an injectable (Sandostatin, Sandostatin LAR, generics). It has been approved in many countries since 1988. Structure and properties Octreotide is a synthetic octapeptide derivative of the hormone somatostatin. It is present in the drug as octreotide acetate and has the following structure: D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-ol, xCH3COOH (x = 1.4 to 2.5). … Octreotide
Products Ofatumumab was approved in 2009 as a concentrate for the preparation of an infusion solution for leukemia treatment (Arzerra). In 2020, a solution for injection was approved in the United States for MS treatment (Kesimpta). Structure and properties Ofatumumab is a human IgG1 monoclonal antibody produced by biotechnological methods. It has a molecular mass … Ofatumumab
Products Golimumab is commercially available as a solution for injection (Simponi). It was approved in many countries in 2010. Structure and properties Golimumab (Mr = 150 kDa) is a human IgG1κ-monoclonal antibody. Effects Golimumab (ATC L04AB06) has selective immunosuppressive and anti-inflammatory properties. The effects are based on binding to the soluble and membrane-bound proinflammatory cytokine … Golimumab
Products TNF-α inhibitors are commercially available as injectable and infusion preparations. Infliximab (Remicade) was the first agent from this group to be approved in 1998, and in many countries in 1999. Biosimilars of some representatives are now available. Others will follow in the next few years. This article refers to biologics. Small molecules can also … TNF-Α Inhibitors
Products In many countries, injection solutions containing ferric carboxymaltose (Ferinject, 2007), ferrous sucrose (Venofer, 1949), ferumoxytol (Rienso, 2012), and ferric derisomaltose (ferric isomaltoside, Monofer, 2019) are commercially available. In other countries, other products with different compositions are available, for example, ferrous sodium gluconate. Iron dextrans are rarely used anymore because of the risk for severe … Iron Infusions
Products Injection preparations are approved as medicinal products. Structure and properties Injection preparations are sterile solutions, emulsions, or suspensions prepared by dissolving, emulsifying, or suspending the active ingredient and excipients in water or a suitable nonaqueous liquid (e.g., fatty oils). Compared with infusions, these are usually small volumes in the range of less than a … Injections
Products Lokivetmab was approved in the EU in 2017 and in many countries in 2018 in the form of a solution for injection (Cytopoint, Zoetis Belgium SA). Lokivetmab was the first monoclonal antibody to be cleared for animals. In the United States, locivetmab was approved in 2015 (Canine Atopic Dermatitis Immunotherapeutic). Structure and properties Lokivetmab … Lokivetmab
Products Lixisenatide was approved as a subcutaneous solution for injection in the EU in 2012, in the United States in 2016, and in many countries in 2017 (Lyxumia). Lixisenatide is also combined with insulin glargine; see iGlarLixi (Suliqua). Structure and properties Lixisenatide is a peptide and GLP1 analog of 44 amino acids that, like exenatide, … Lixisenatide
Products Chickenpox vaccine is commercially available as an injectable in many countries (e.g., Varivax). It can also be combined fixed with the MMR vaccine (= MMRV vaccine). Structure and properties This is a live attenuated vaccine containing varicella-zoster virus of the OKA/Merck strain grown in human cells. This strain was developed in Japan in the … Chickenpox Vaccination